16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and cell culture studies suggest inhibiting MGMT or its downstream mediator USP17L2 alone or in combination with HDAC inhibitors could help treat ovarian cancer. In patients, high tumor expression of...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
02:20 , Jan 18, 2019 |  BC Innovations  |  Targets & Mechanisms

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest the HDAC inhibitor entinostat alone or in combination with chemotherapy could help treat alveolar rhabdomyosarcoma. In an orthotopic mouse model of alveolar rhabdomyosarcoma, entinostat decreased tumor growth compared with vehicle,...
14:42 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
19:12 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Dec. 4 and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral...
20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
21:29 , Dec 4, 2018 |  BC Extra  |  Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Tuesday and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral to...
20:10 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest miR-584-5p could help treat medulloblastoma. In patient tissue samples or tumor cells from patient-derived xenograft (PDX) mouse models of medulloblastoma, miR-584-5p levels were lower...
18:51 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid...